[Secondary anticoagulant prophylaxis with low molecular heparins or oral anticoagulants and bone mineral density].
A broad spectrum of indications for low molecular weight heparin (LMWH) requires an assessment of side effects especially during prolonged administration. There are common risk factors for venous thromboembolism (VTE) and osteoporosis; heparin is "the drug of choice" for VTE treatment. The aim of our study was to assess the effect of treatment and prophylaxis with LMWH (enoxaparine sodium) and oral anticoagulant (acenocoumarol) for bone structure. Material consists of in- and outpatients. 49 densitometries were performed in 31 patients (in 15 cases double examination). We observed a decrease of bone mineral density in comparison to the initial examination in most cases: mean change of bone mass for examined areas was 3.05%.
Wawrzyńska
L
L
Klinika Chorób Wewnetrznych Klatki Piersiowej Instytutu Gruźlicy i Chorób Płuc w Warszawie.
Przedlacki
J
J
Hajduk
B
B
Tomkowski
W
W
Fijałkowska
A
A
Ostrowski
K
K
Torbicki
A
A
D000074:Acenocoumarol / Q000008:administration & dosage / Q000009:adverse effects*; D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects*; D015519:Bone Density / Q000187:drug effects*; D005260:Female; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000139:chemically induced / Q000517:prevention & control; D012307:Risk Factors; D013924:Thrombophlebitis / Q000517:prevention & control
D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; D000074:Acenocoumarol